Aims/hypothesis Clinical trials assessing interventions for treating and preventing diabetes
mellitus and its complications are needed to inform evidence-based practice. To examine …

Context Concerns about the safety and efficacy of diabetes interventions persist, in part
because randomized clinical trials (RCTs) have not measured their effect on patient …

Glycaemic control is an inadequate surrogate marker of cardiovascular event reduction in
patients with type 2 diabetes. Clinical trials to date have been unsuccessful in identifying a …

In 2008, the US Food and Drug Administration (FDA) issued guidance requiring robust
assessment of cardiovascular safety for all antidiabetic drugs to be licensed in the future …

Few trials of glucose-lowering drugs or strategies in people with type 2 diabetes have
investigated cardiovascular outcomes, even though most patients die from cardiovascular …

Purpose A better understanding of the current features of type 2 diabetes mellitus (T2DM)-
related clinical trials is important for improving designs of clinical trials and identifying …

Aims To investigate cardiovascular disease and mortality trends in control arm participants
of diabetes cardiovascular outcome trials (CVOTs). Methods We electronically searched …

BACKGROUND: Food and Drug Administration guidance now proposes that cardiovascular
safety of new diabetes medicines be demonstrated. Consequently, trials should include a …

Responding to concerns about the potential for increased risk of adverse cardiovascular
outcomes, specifically myocardial infarction, associated with certain glucose-lowering …

Diabetes medications and cardiovascular outcome trials: Lessons learned. - Abstract - Europe
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers …